D-Chiro-Inositol in Endometrial Hyperplasia: A Pilot Study.
Giuseppina PorcaroGabriele BilottaElena CapocciaMaria Salomé Bezerra EspinolaCesare AragonaPublished in: International journal of molecular sciences (2023)
Endometrial hyperplasia is a threatening pathology driven by unopposed estrogen stimulus. Moreover, insulin may act on the endometrium, prompting further growth. We aimed at assessing whether D-chiro-Inositol, an insulin sensitizer with estrogen-lowering properties, might improve the condition of patients with simple endometrial hyperplasia without atypia. We enrolled women with simple endometrial hyperplasia without atypia and related symptoms, including abnormal uterine bleeding. We treated the patients with one tablet per day, containing 600 mg of D-chiro-inositol for six months. Patients underwent ultrasound to assess the thickness of the endometrium at baseline, after three months, and at the end of this study. Endometrial thickness went from 10.82 ± 1.15 mm to 8.00 ± 0.81 mm after three months ( p < 0.001) and to 6.9 ± 1.06 mm after six months ( p < 0.001 versus baseline; p < 0.001 versus three months). D-chiro-inositol treatment also improved heavy menstrual bleeding and the length of menstruation. Despite the fact that our data should be validated in larger studies with appropriate control groups, our promising results support the hypothesis that D-chiro-inositol may represent a useful treatment in the case of endometrial hyperplasia without atypia.
Keyphrases
- endometrial cancer
- type diabetes
- end stage renal disease
- newly diagnosed
- atrial fibrillation
- ejection fraction
- chronic kidney disease
- optical coherence tomography
- metabolic syndrome
- computed tomography
- prognostic factors
- glycemic control
- insulin resistance
- depressive symptoms
- peritoneal dialysis
- skeletal muscle
- combination therapy
- deep learning
- smoking cessation
- patient reported outcomes
- contrast enhanced ultrasound